Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Ovarian Neoplasms 40Breast Neoplasms 14Uterine Cervical Neoplasms 13Melanoma 13Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 8Head and Neck Neoplasms 8Stomach Neoplasms 7Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Esophageal Neoplasms 6Anus Neoplasms 6Vaginal Neoplasms 5Penile Neoplasms 5Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Carcinoma, Hepatocellular 5Vulvar Neoplasms 4Urogenital Neoplasms 4Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma, Synovial 4Oropharyngeal Neoplasms 4Neoplasms 4Multiple Myeloma 4Mesothelioma 4Carcinoma, Renal Cell 4Recurrence 3

Interventions

pembrolizumab 4atezolizumab 2Nivolumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × fludarabine × Gynecologic × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡